Oruka Therapeutics Q2 net loss widens on higher R&D costs

Oruka Therapeutics

10/08/2026 12:20

Overview
US biotech developer reported Q2 net loss widened yr/yr, driven by higher R&D expenses
Company ended Q2 with $1.1 bln in cash, expected to fund operations through BLA filing
Several clinical milestones expected in coming quarters for lead biologics targeting skin diseases

Outlook
Oruka expects EVERLAST-A Week 28 data at end of 3Q 2026, 52-week data in Dec 2026
Company expects EVERLAST-B Week 16 data in 4Q 2026, ORCA-SURGE Week 16 data in 1Q 2027
Oruka expects cash to fund operations through a BLA filing for ORKA-001 and ORKA-002 development

Result Drivers
R&D SPENDING - Higher research and development expenses driven by additional clinical trials, a licensing payment, and increased employee compensation
ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher compensation and public company costs
INTEREST INCOME - Other income increased mainly from interest earned on higher cash and marketable securities

Company press release: ID:nGNX5k8V7v

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.55
 
Q2 Net Loss
 
$41.21 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Oruka Therapeutics Inc is $150.00, about 51.8% above its August 7 closing price of $98.82

Reuters Recommended Reads
Aug 7 - Israel's Entera Bio Q2 net loss widens 
Aug 7 - Soligenix Q2 net loss narrows as R&D expenses fall
Aug 7 - ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)